<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35065969</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>298</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>A copper chaperone-mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>101612</StartPage><MedlinePgn>101612</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101612</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2022.101612</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(22)00052-7</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease in which motor neurons progressively and rapidly degenerate, eventually leading to death. The first protein found to contain ALS-associated mutations was copper/zinc superoxide dismutase 1 (SOD1), which is conformationally stable when it contains its metal ligands and has formed its native intramolecular disulfide. Mutations in SOD1 reduce protein folding stability via disruption of metal binding and/or disulfide formation, resulting in misfolding, aggregation, and ultimately cellular toxicity. A great deal of effort has focused on preventing the misfolding and aggregation of SOD1 as a potential therapy for ALS; however, the results have been mixed. Here, we utilize a small-molecule polytherapy of diacetylbis(N(4)-methylthiosemicarbazonato)copper(II) (CuATSM) and ebselen to mimic the metal delivery and disulfide bond promoting activity of the cellular chaperone of SOD1, the "copper chaperone for SOD1." Using microscopy with automated image analysis, we find that polytherapy using CuATSM and ebselen is highly effective and acts in synergy to reduce inclusion formation in a cell model of SOD1 aggregation for multiple ALS-associated mutants. Polytherapy reduces mutant SOD1-associated cell death, as measured by live-cell microscopy. Measuring dismutase activity via zymography and immunoblotting for disulfide formation showed that polytherapy promoted more effective maturation of transfected SOD1 variants beyond either compound alone. Our data suggest that a polytherapy of CuATSM and ebselen may merit more study as an effective method of treating SOD1-associated ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McAlary</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia; Faculty of Science, Medicine and Health, Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, New South Wales, Australia. Electronic address: lmcalary@uow.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shephard</LastName><ForeName>V K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia; Faculty of Science, Medicine and Health, Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>G S A</ForeName><Initials>GSA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerbury</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, New South Wales, Australia; Faculty of Science, Medicine and Health, Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, New South Wales, Australia. Electronic address: jyerbury@uow.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>WRIGHT/OCT18/969-799</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000720849">CuATSM</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004220">Disulfides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054833">Isoindoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091343">Organocopper Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016566">Organoselenium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>40X2P7DPGH</RegistryNumber><NameOfSubstance UI="C042986">ebselen</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040761" MajorTopicYN="N">Biomimetic Materials</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="N">Copper</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004220" MajorTopicYN="N">Disulfides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054833" MajorTopicYN="N">Isoindoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091343" MajorTopicYN="Y">Organocopper Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016566" MajorTopicYN="N">Organoselenium Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="Y">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CuATSM</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">ebselen</Keyword><Keyword MajorTopicYN="N">protein aggregation</Keyword><Keyword MajorTopicYN="N">protein folding</Keyword><Keyword MajorTopicYN="N">superoxide dismutase 1</Keyword></KeywordList><CoiStatement>Conflict of interest L. M. reports that financial support was provided by Motor Neurone Disease Research Australia. L. M. reports a relationship with University of Wollongong Illawarra Health and Medical Research Institute and Molecular Horizons Fluorescence Analysis Facility, both of which includes nonfinancial support. G. S. A. W. reports that financial support was provided by Motor Neurone Disease Association. All other authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>23</Day><Hour>20</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35065969</ArticleId><ArticleId IdType="pmc">PMC8885447</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2022.101612</ArticleId><ArticleId IdType="pii">S0021-9258(22)00052-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wroe R., Wai-Ling Butler A., Andersen P.M., Powell J.F., Al-Chalabi A. ALSOD: The amyotrophic lateral sclerosis online database. Amyotroph. Lateral Scler. 2008;9:249&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608099</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Aquilina J.A., Yerbury J.J. Susceptibility of mutant SOD1 to form a destabilized monomer predicts cellular aggregation and toxicity but not in&#xa0;vitro aggregation propensity. Front. Neurosci. 2016;10:499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5095133</ArticleId><ArticleId IdType="pubmed">27867347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg M.J., Bystr&#xf6;m R., Bokn&#xe4;s N., Andersen P.M., Oliveberg M. Systematically perturbed folding patterns of amyotrophic lateral sclerosis (ALS)-associated SOD1 mutants. Proc. Natl. Acad. Sci. U.&#xa0;S. A. 2005;102:9754&#x2013;9759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1174986</ArticleId><ArticleId IdType="pubmed">15987780</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor E.A., Fee L., Tao Y., Redler R.L., Fay J.M., Zhang Y., Lv Z., Mercer I.P., Deshmukh M., Lyubchenko Y.L., Dokholyan N.V. Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2016;113:614&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725519</ArticleId><ArticleId IdType="pubmed">26719414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C., Beck M.V., Griffith J.D., Deshmukh M., Dokholyan N.V. Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2018;115:4661&#x2013;4665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939103</ArticleId><ArticleId IdType="pubmed">29666246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill C., Phelan J.P., Hatzipetros T., Kidd J.D., Tassinari V.R., Levine B., Wang M.Z., Moreno A., Thompson K., Maier M., Grimm J., Gill A., Vieira F.G. SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Sci. Rep. 2019;9:6724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491559</ArticleId><ArticleId IdType="pubmed">31040321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang L., Zetterstr&#xf6;m P., Br&#xe4;nnstr&#xf6;m T., Marklund S.L., Danielsson J., Oliveberg M. SOD1 aggregation in ALS mice shows simplistic test tube behavior. Proc. Natl. Acad. Sci. U. S. A. 2015;112:9878&#x2013;9883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4538623</ArticleId><ArticleId IdType="pubmed">26221023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg M.J., Tibell L., Oliveberg M. Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: Decreased stability of the apo state. Proc. Natl. Acad. Sci. U. S. A. 2002;99:16607&#x2013;16612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139191</ArticleId><ArticleId IdType="pubmed">12482932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang L., Kurnik M., Danielsson J., Oliveberg M. Fibrillation precursor of superoxide dismutase 1 revealed by gradual tuning of the protein-folding equilibrium. Proc. Natl. Acad. Sci. U. S. A. 2012;109:17868&#x2013;17873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3497812</ArticleId><ArticleId IdType="pubmed">22797895</ArticleId></ArticleIdList></Reference><Reference><Citation>Oztug Durer Z.A., Cohlberg J.A., Dinh P., Padua S., Ehrenclou K., Downes S., Tan J.K., Nakano Y., Bowman C.J., Hoskins J.L., Kwon C., Mason A.Z., Rodriguez J.A., Doucette P.A., Shaw B.F., et al. Loss of metal ions, disulfide reduction and mutations related to familial ALS promote formation of amyloid-like aggregates from superoxide dismutase. PLoS One. 2009;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659422</ArticleId><ArticleId IdType="pubmed">19325915</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L., Bertini I., Cantini F., D'Amelio N., Gaggelli E. Human SOD1 before harboring the catalytic metal: Solution structure of copper-depleted, disulfide-reduced form. J.&#xa0;Biol. Chem. 2006;281:2333&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pubmed">16291742</ArticleId></ArticleIdList></Reference><Reference><Citation>Culotta V.C., Klomp L.W., Strain J., Casareno R.L., Krems B., Gitlin J.D. The copper chaperone for superoxide dismutase. J.&#xa0;Biol. Chem. 1997;272:23469&#x2013;23472.</Citation><ArticleIdList><ArticleId IdType="pubmed">9295278</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Torres A.S., O'Halloran T.V. Oxygen-induced maturation of SOD1: A key role for disulfide formation by the copper chaperone CCS. EMBO J. 2004;23:2872&#x2013;2881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1150991</ArticleId><ArticleId IdType="pubmed">15215895</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L., Bertini I., Cantini F., Kozyreva T., Massagni C., Palumaa P., Rubino J.T., Zovo K. Human superoxide dismutase 1 (hSOD1) maturation through interaction with human copper chaperone for SOD1 (hCCS) Proc. Natl. Acad. Sci. U. S. A. 2012;109:13555&#x2013;13560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427097</ArticleId><ArticleId IdType="pubmed">22869735</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine J.S., Doucette P.A., Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem. 2005;74:563&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">15952898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright G.S.A., Antonyuk S.V., Hasnain S.S. The biophysics of superoxide dismutase-1 and amyotrophic lateral sclerosis. Q.&#xa0;Rev. Biophys. 2019;52</Citation><ArticleIdList><ArticleId IdType="pubmed">31760962</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskin I., Forsgren E., Lehmann M., Andersen P.M., Br&#xe4;nnstr&#xf6;m T., Lange D.J., Synofzik M., Nordstr&#xf6;m U., Zetterstr&#xf6;m P., Marklund S.L., Gilthorpe J.D. The molecular pathogenesis of superoxide dismutase 1-linked ALS is promoted by low oxygen tension. Acta Neuropathol. 2019;138:85&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570705</ArticleId><ArticleId IdType="pubmed">30863976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyay M., Durazo A., Sohn S.H., Strong C.D., Gralla E.B., Whitelegge J.P., Valentine J.S. Initiation and elongation in fibrillation of ALS-linked superoxide dismutase. Proc. Natl. Acad. Sci. U.&#xa0;S. A. 2008;105:18663&#x2013;18668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585484</ArticleId><ArticleId IdType="pubmed">19022905</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Kaneko K., Yamanaka K., O&#x2019;Halloran T.V., Nukina N. Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis. J.&#xa0;Biol. Chem. 2008;283:24167&#x2013;24176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259764</ArticleId><ArticleId IdType="pubmed">18552350</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassall K.A., Stubbs H.R., Primmer H.A., Tong M.S., Sullivan S.M., Sobering R., Srinivasan S., Briere L.A., Dunn S.D., Col&#xf3;n W., Meiering E.M. Decreased stability and increased formation of soluble aggregates by immature superoxide dismutase do not account for disease severity in ALS. Proc. Natl. Acad. Sci. U. S. A. 2011;108:2210&#x2013;2215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038722</ArticleId><ArticleId IdType="pubmed">21257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Graffmo K.S., Forsberg K., Bergh J., Birve A., Zetterstr&#xf6;m P., Andersen P.M., Marklund S.L., Br&#xe4;nnstr&#xf6;m T. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:51&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23026746</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Yerbury J.J., Aquilina J.A. Glutathionylation potentiates benign superoxide dismutase 1 variants to the toxic forms associated with amyotrophic lateral sclerosis. Sci. Rep. 2013;3:3275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834562</ArticleId><ArticleId IdType="pubmed">24253732</ArticleId></ArticleIdList></Reference><Reference><Citation>Broom H.R., Rumfeldt J.A., Vassall K.A., Meiering E.M. Destabilization of the dimer interface is a common consequence of diverse ALS-associated mutations in metal free SOD1. Protein Sci. 2015;24:2081&#x2013;2089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815230</ArticleId><ArticleId IdType="pubmed">26362407</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell N.E., Lambert-Smith I., Mitchell K., McKenna J., McAlary L., Ciryam P., Vine K.L., Saunders D.N., Yerbury J.J. SOD1A4V aggregation alters ubiquitin homeostasis in a cell model of ALS. J.&#xa0;Cell Sci. 2018;131</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919637</ArticleId><ArticleId IdType="pubmed">29748379</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., Maragakis N.J., McDermott C.J., Pestronk A., Ravits J., Salachas F., et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N.&#xa0;Engl. J. Med. 2020;383:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Wuu J., Andersen P.M., Atassi N., David W., Cudkowicz M., Schoenfeld D. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565&#x2013;e574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818014</ArticleId><ArticleId IdType="pubmed">29367439</ArticleId></ArticleIdList></Reference><Reference><Citation>DuVal M.G., Hinge V.K., Snyder N., Kanyo R., Bratvold J., Pokrishevsky E., Cashman N.R., Blinov N., Kovalenko A., Allison W.T. Tryptophan 32 mediates SOD1 toxicity in a in&#xa0;vivo motor neuron model of ALS and is a promising target for small molecule therapeutics. Neurobiol. Dis. 2019;124:297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">30528257</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrishevsky E., McAlary L., Farrawell N.E., Zhao B., Sher M., Yerbury J.J., Cashman N.R. Tryptophan 32-mediated SOD1 aggregation is attenuated by pyrimidine-like compounds in living cells. Sci. Rep. 2018;8:15590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197196</ArticleId><ArticleId IdType="pubmed">30349065</ArticleId></ArticleIdList></Reference><Reference><Citation>Capper M.J., Wright G.S.A., Barbieri L., Luchinat E., Mercatelli E., McAlary L., Yerbury J.J., O'Neill P.M., Antonyuk S.V., Banci L., Hasnain S.S. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. Nat. Commun. 2018;9:1693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5923229</ArticleId><ArticleId IdType="pubmed">29703933</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts B.R., Lim N.K., McAllum E.J., Donnelly P.S., Hare D.J., Doble P.A., Turner B.J., Price K.A., Lim S.C., Paterson B.M., Hickey J.L., Rhoads T.W., Williams J.R., Kanninen K.M., Hung L.W., et al. Oral treatment with CuII(atsm) increases mutant SOD1 in&#xa0;vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J.&#xa0;Neurosci. 2014;34:8021&#x2013;8031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608261</ArticleId><ArticleId IdType="pubmed">24899723</ArticleId></ArticleIdList></Reference><Reference><Citation>Rando A., de la Torre M., Martinez-Muriana A., Zaragoza P., Musaro A., Hern&#xe1;ndez S., Navarro X., Toivonen J.M., Osta R. Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS. PLoS One. 2019;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331125</ArticleId><ArticleId IdType="pubmed">30640943</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchinat E., Barbieri L., Banci L. A&#xa0;molecular chaperone activity of CCS restores the maturation of SOD1 fALS mutants. Sci. Rep. 2017;7:17433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5727297</ArticleId><ArticleId IdType="pubmed">29234142</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala F.A., Wright G.S.A., Antonyuk S.V., Garratt R.C., Hasnain S.S. Molecular recognition and maturation of SOD1 by its evolutionarily destabilised cognate chaperone hCCS. PLoS Biol. 2019;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6383938</ArticleId><ArticleId IdType="pubmed">30735496</ArticleId></ArticleIdList></Reference><Reference><Citation>Proescher J.B., Son M., Elliott J.L., Culotta V.C. Biological effects of CCS in the absence of SOD1 enzyme activation: Implications for disease in a mouse model for ALS. Hum. Mol. Genet. 2008;17:1728&#x2013;1737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900889</ArticleId><ArticleId IdType="pubmed">18337307</ArticleId></ArticleIdList></Reference><Reference><Citation>Son M., Fu Q., Puttaparthi K., Matthews C.M., Elliott J.L. Redox susceptibility of SOD1 mutants is associated with the differential response to CCS over-expression in&#xa0;vivo. Neurobiol. Dis. 2009;34:155&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2835407</ArticleId><ArticleId IdType="pubmed">19320055</ArticleId></ArticleIdList></Reference><Reference><Citation>Son M., Puttaparthi K., Kawamata H., Rajendran B., Boyer P.J., Manfredi G., Elliott J.L. Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology. Proc. Natl. Acad. Sci. U. S. A. 2007;104:6072&#x2013;6077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851618</ArticleId><ArticleId IdType="pubmed">17389365</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton J.B., Mercer S.W., Lim N.K., Faux N.G., Buncic G., Beckman J.S., Roberts B.R., Donnelly P.S., White A.R., Crouch P.J. CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Sci. Rep. 2017;7:42292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5304223</ArticleId><ArticleId IdType="pubmed">28205575</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira F.G., Hatzipetros T., Thompson K., Moreno A.J., Kidd J.D., Tassinari V.R., Levine B., Perrin S., Gill A. CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits. IBRO Rep. 2017;2:47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6084867</ArticleId><ArticleId IdType="pubmed">30135932</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams J.R., Trias E., Beilby P.R., Lopez N.I., Labut E.M., Bradford C.S., Roberts B.R., McAllum E.J., Crouch P.J., Rhoads T.W., Pereira C., Son M., Elliott J.L., Franco M.C., Est&#xe9;vez A.G., et al. Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the copper-chaperone-for-SOD. Neurobiol. Dis. 2016;89:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4785045</ArticleId><ArticleId IdType="pubmed">26826269</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell N.E., Yerbury M.R., Plotkin S.S., McAlary L., Yerbury J.J. CuATSM protects against the in&#xa0;vitro cytotoxicity of wild-type-like copper&#x2013;zinc superoxide dismutase mutants but not mutants that disrupt metal binding. ACS Chem. Neurosci. 2019;10:1555&#x2013;1564.</Citation><ArticleIdList><ArticleId IdType="pubmed">30462490</ArticleId></ArticleIdList></Reference><Reference><Citation>Chantadul V., Wright G.S.A., Amporndanai K., Shahid M., Antonyuk S.V., Washbourn G., Rogers M., Roberts N., Pye M., O'Neill P.M., Hasnain S.S. Ebselen as template for stabilization of A4V mutant dimer for motor neuron disease therapy. Commun. Biol. 2020;3:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058017</ArticleId><ArticleId IdType="pubmed">32139772</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh-Hashi K., Hirata Y. Elucidation of the molecular characteristics of wild-type and ALS-linked mutant SOD1 using the NanoLuc complementation reporter system. Appl. Biochem. Biotechnol. 2020;190:674&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">31422561</ArticleId></ArticleIdList></Reference><Reference><Citation>Amporndanai K., Rogers M., Watanabe S., Yamanaka K., O&#x2019;Neill P.M., Hasnain S.S. Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis. EBioMedicine. 2020;59:102980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456458</ArticleId><ArticleId IdType="pubmed">32862101</ArticleId></ArticleIdList></Reference><Reference><Citation>Crown A.M., Roberts B.L., Crosby K., Brown H., Ayers J.I., Hart P.J., Borchelt D.R. Experimental mutations in superoxide dismutase 1 provide insight into potential mechanisms involved in aberrant aggregation in familial amyotrophic lateral sclerosis. G3 (Bethesda) 2019;9:719&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6404617</ArticleId><ArticleId IdType="pubmed">30622123</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby K., Crown A.M., Roberts B.L., Brown H., Ayers J.I., Borchelt D.R. Loss of charge mutations in solvent exposed Lys residues of superoxide dismutase 1 do not induce inclusion formation in cultured cell models. PLoS One. 2018;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219784</ArticleId><ArticleId IdType="pubmed">30399166</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner B.J., Atkin J.D., Farg M.A., Zang D.W., Rembach A., Lopes E.C., Patch J.D., Hill A.F., Cheema S.S. Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis. J.&#xa0;Neurosci. 2005;25:108&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725218</ArticleId><ArticleId IdType="pubmed">15634772</ArticleId></ArticleIdList></Reference><Reference><Citation>Crown A., McAlary L., Fagerli E., Brown H., Yerbury J.J., Galaleldeen A., Cashman N.R., Borchelt D.R., Ayers J.I. Tryptophan residue 32 in human Cu-Zn superoxide dismutase modulates prion-like propagation and strain selection. PLoS One. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6991973</ArticleId><ArticleId IdType="pubmed">31999698</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiten D.R., San Gil R., McAlary L., Yerbury J.J., Ecroyd H., Wilson M.R. Rapid flow cytometric measurement of protein inclusions and nuclear trafficking. Sci. Rep. 2016;6:31138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4981889</ArticleId><ArticleId IdType="pubmed">27516358</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones T.R., Carpenter A.E., Lamprecht M.R., Moffat J., Silver S.J., Grenier J.K., Castoreno A.B., Eggert U.S., Root D.E., Golland P., Sabatini D.M. Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc. Natl. Acad. Sci. U. S. A. 2009;106:1826&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2634799</ArticleId><ArticleId IdType="pubmed">19188593</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuin C., Goodman A., Chernyshev V., Kamentsky L., Cimini B.A., Karhohs K.W., Doan M., Ding L., Rafelski S.M., Thirstrup D., Wiegraebe W., Singh S., Becker T., Caicedo J.C., Carpenter A.E. CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol. 2018;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029841</ArticleId><ArticleId IdType="pubmed">29969450</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X., Antonyuk S.V., Seetharaman S.V., Whitson L.J., Taylor A.B., Holloway S.P., Strange R.W., Doucette P.A., Valentine J.S., Tiwari A., Hayward L.J., Padua S., Cohlberg J.A., Hasnain S.S., Hart P.J. Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis. J.&#xa0;Biol. Chem. 2008;283:16169&#x2013;16177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2414278</ArticleId><ArticleId IdType="pubmed">18378676</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonyuk S., Elam J.S., Hough M.A., Strange R.W., Doucette P.A., Rodriguez J.A., Hayward L.J., Valentine J.S., Hart P.J., Hasnain S.S. Structural consequences of the familial amyotrophic lateral sclerosis SOD1 mutant His46Arg. Protein Sci. 2005;14:1201&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253262</ArticleId><ArticleId IdType="pubmed">15840828</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Nilsson P., Ker&#xe4;nen M.L., Forsgren L., H&#xe4;gglund J., Karlsborg M., Ronnevi L.O., Gredal O., Marklund S.L. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain. 1997;120:1723&#x2013;1737.</Citation><ArticleIdList><ArticleId IdType="pubmed">9365366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayat Mokhtari R., Homayouni T.S., Baluch N., Morgatskaya E., Kumar S., Das B., Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8:38022&#x2013;38043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5514969</ArticleId><ArticleId IdType="pubmed">28410237</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Hou J., Ping J., Cai D. Advances in developing novel therapeutic strategies for Alzheimer&#x2019;s disease. Mol. Neurodegener. 2018;13:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6291983</ArticleId><ArticleId IdType="pubmed">30541602</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Plotkin S.S., Cashman N.R. Emerging developments in targeting proteotoxicity in neurodegenerative diseases. CNS Drugs. 2019;33:883&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776490</ArticleId><ArticleId IdType="pubmed">31414322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav B., Wennerberg K., Aittokallio T., Tang J. Searching for drug synergy in complex dose&#x2013;response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 2015;13:504&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759128</ArticleId><ArticleId IdType="pubmed">26949479</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Veroli G.Y., Fornari C., Wang D., Mollard S., Bramhall J.L., Richards F.M., Jodrell D.I. Combenefit: An interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32:2866&#x2013;2868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018366</ArticleId><ArticleId IdType="pubmed">27153664</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnesano F., Banci L., Bertini I., Martinelli M., Furukawa Y., O'Halloran T.V. The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J.&#xa0;Biol. Chem. 2004;279:47998&#x2013;48003.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326189</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchinat E., Barbieri L., Rubino J.T., Kozyreva T., Cantini F., Banci L. In-cell NMR reveals potential precursor of toxic species from SOD1 fALS mutants. Nat. Commun. 2014;5:5502.</Citation><ArticleIdList><ArticleId IdType="pubmed">25429517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward L.J., Rodriguez J.A., Kim J.W., Tiwari A., Goto J.J., Cabelli D.E., Valentine J.S., Brown R.H. Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. J.&#xa0;Biol. Chem. 2002;277:15923&#x2013;15931.</Citation><ArticleIdList><ArticleId IdType="pubmed">11854284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari A., Hayward L.J. Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. J.&#xa0;Biol. Chem. 2003;278:5984&#x2013;5992.</Citation><ArticleIdList><ArticleId IdType="pubmed">12458194</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchamp C., Fridovich I. Superoxide dismutase: Improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 1971;44:276&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">4943714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sea K., Sohn S.H., Durazo A., Sheng Y., Shaw B.F., Cao X., Taylor A.B., Whitson L.J., Holloway S.P., Hart P.J., Cabelli D.E., Gralla E.B., Valentine J.S. Insights into the role of the unusual disulfide bond in copper-zinc superoxide dismutase. J.&#xa0;Biol. Chem. 2015;290:2405&#x2013;2418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303690</ArticleId><ArticleId IdType="pubmed">25433341</ArticleId></ArticleIdList></Reference><Reference><Citation>Auclair J.R., Boggio K.J., Petsko G.A., Ringe D., Agar J.N. Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2010;107:21394&#x2013;21399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3003092</ArticleId><ArticleId IdType="pubmed">21098299</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly D.P., Dowgiallo M.G., Salisbury J.P., Aluri K.C., Iyengar S., Chaudhari M., Mathew M., Miele I., Auclair J.R., Lopez S.A., Manetsch R., Agar J.N. Cyclic thiosulfinates and cyclic disulfides selectively cross-link thiols while avoiding modification of lone thiols. J.&#xa0;Am. Chem. Soc. 2018;140:7377&#x2013;7380.</Citation><ArticleIdList><ArticleId IdType="pubmed">29851341</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Yerbury J.J. Strategies to promote the maturation of ALS-associated SOD1 mutants: Small molecules return to the fold. Neural Regen. Res. 2019;14:1511&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6557088</ArticleId><ArticleId IdType="pubmed">31089043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S.S., Nowak R.J., Strokovich K., Brown R.H., Jr., Walz T., Lansbury P.T., Jr. An intersubunit disulfide bond prevents in&#xa0;vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis. Biochemistry. 2004;43:4899&#x2013;4905.</Citation><ArticleIdList><ArticleId IdType="pubmed">15109247</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammarstr&#xf6;m P., Wiseman R.L., Powers E.T., Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">12560553</ArticleId></ArticleIdList></Reference><Reference><Citation>Stathopulos P.B., Rumfeldt J.A., Karbassi F., Siddall C.A., Lepock J.R., Meiering E.M. Calorimetric analysis of thermodynamic stability and aggregation for apo and holo amyotrophic lateral sclerosis-associated Gly-93 mutants of superoxide dismutase. J.&#xa0;Biol. Chem. 2006;281:6184&#x2013;6193.</Citation><ArticleIdList><ArticleId IdType="pubmed">16407238</ArticleId></ArticleIdList></Reference><Reference><Citation>Doucette P.A., Whitson L.J., Cao X., Schirf V., Demeler B., Valentine J.S., Hansen J.C., Hart P.J. Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant. Insights into the molecular basis for dimer stability. J.&#xa0;Biol. Chem. 2004;279:54558&#x2013;54566.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg M.J., Normark J., Holmgren A., Oliveberg M. Folding of human superoxide dismutase: Disulfide reduction prevents dimerization and produces marginally stable monomers. Proc. Natl. Acad. Sci. U. S. A. 2004;101:15893&#x2013;15898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC528748</ArticleId><ArticleId IdType="pubmed">15522970</ArticleId></ArticleIdList></Reference><Reference><Citation>Corson L.B., Strain J.J., Culotta V.C., Cleveland D.W. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc. Natl. Acad. Sci. U. S. A. 1998;95:6361&#x2013;6366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27707</ArticleId><ArticleId IdType="pubmed">9600970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright G.S., Antonyuk S.V., Kershaw N.M., Strange R.W., Samar Hasnain S. Ligand binding and aggregation of pathogenic SOD1. Nat. Commun. 2013;4:1758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3644087</ArticleId><ArticleId IdType="pubmed">23612299</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R., Meng H., Wongkongkathep P., Corrales C.I., Sepanj N., Atlasi R.S., Kl&#xe4;rner F.G., Schrader T., Spencer M.J., Loo J.A., Wiedau M., Bitan G. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in&#xa0;vitro and in the G93A-SOD1 mouse model of ALS. J.&#xa0;Biol. Chem. 2019;294:3501&#x2013;3513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416427</ArticleId><ArticleId IdType="pubmed">30602569</ArticleId></ArticleIdList></Reference><Reference><Citation>Kil J., Pierce C., Tran H., Gu R., Lynch E.D. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007;226:44&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kil J., Lobarinas E., Spankovich C., Griffiths S.K., Antonelli P.J., Lynch E.D., Le Prell C.G. Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;390:969&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pubmed">28716314</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker S.J., Meyerowitz J., James J.L., Liddell J.R., Nonaka T., Hasegawa M., Kanninen K.M., Lim S., Paterson B.M., Donnelly P.S., Crouch P.J., White A.R. Inhibition of TDP-43 accumulation by bis(thiosemicarbazonato)-copper complexes. PLoS One. 2012;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3411774</ArticleId><ArticleId IdType="pubmed">22879928</ArticleId></ArticleIdList></Reference><Reference><Citation>Soon C.P., Donnelly P.S., Turner B.J., Hung L.W., Crouch P.J., Sherratt N.A., Tan J.L., Lim N.K., Lam L., Bica L., Lim S., Hickey J.L., Morizzi J., Powell A., Finkelstein D.I., et al. Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II) (CuII(atsm)) protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model. J.&#xa0;Biol. Chem. 2011;286:44035&#x2013;44044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243559</ArticleId><ArticleId IdType="pubmed">22033929</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury J.J., Farrawell N.E., McAlary L. Proteome homeostasis dysfunction: A unifying principle in ALS pathogenesis. Trends Neurosci. 2020;43:274&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">32353332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange D.J., Andersen P.M., Remanan R., Marklund S., Benjamin D. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study. Amyotroph. Lateral Scler. Frontotemporal Degener. 2013;14:199&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">22985433</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A., Cole T., Wegener A.J., Tomassy G.S., Setnicka A., Farley B.J., Schoch K.M., Hoye M.L., Shabsovich M., Sun L., Luo Y., Zhang M., Comfort N., Wang B., Amacker J., et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J.&#xa0;Clin. Invest. 2018;128:3558&#x2013;3567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon R.A., Bunton-Stasyshyn R.K., Fisher E.M., Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136:2342&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S., Antel J.P. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 1992;194:209&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1467557</ArticleId></ArticleIdList></Reference><Reference><Citation>Feoktistova M., Geserick P., Leverkus M. Crystal violet assay for determining viability of cultured cells. Cold Spring Harb. Protoc. 2016;2016 pdb.prot087379.</Citation><ArticleIdList><ArticleId IdType="pubmed">27037069</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueden C.T., Schindelin J., Hiner M.C., DeZonia B.E., Walter A.E., Arena E.T., Eliceiri K.W. ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics. 2017;18:529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5708080</ArticleId><ArticleId IdType="pubmed">29187165</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>